Common antidepressant slashes risk of COVID death.

@article{Sidik2021CommonAS,
  title={Common antidepressant slashes risk of COVID death.},
  author={Saima May Sidik},
  journal={Nature},
  year={2021}
}
  • S. Sidik
  • Published 29 October 2021
  • Psychology
  • Nature
View on PubMed
doi.org
3 Citations
Background Citations
1

3 Citations

Citation Type

Citation Type

Difficulty in Repurposing Selective Serotonin Reuptake Inhibitors and Other Antidepressants with Functional Inhibition of Acid Sphingomyelinase in COVID-19 Infection
TLDR
Some prematurely optimistic points of view, promoting a large prescription of fluvoxamine in patients with COVID-19, are thought to be reasonably tempered.
Mechanisms of action of fluvoxamine for COVID-19: a historical review
TLDR
A possible link between maternal COVID-19 infection and a risk for neuropsychiatric disorders and schizophrenia in offspring is discussed and fluvoxamine is the most attractive drug for mild to moderate subjects with CO VID-19.
A critical analysis of SARS-CoV-2 (COVID-19) complexities, emerging variants, and therapeutic interventions and vaccination strategies

References

SHOWING 1-2 OF 2 REFERENCES
Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial
Modulation of the sigma-1 receptor–IRE1 pathway is beneficial in preclinical models of inflammation and sepsis
TLDR
The contribution of S1R to the restraint of the inflammatory response is revealed and this work identifies sigma-1 receptor (S1R) as an essential inhibitor of cytokine production in a preclinical model of septic shock.